Epidermal growth factor receptor (EGFR) mutation status and Rad51 determine the response of glioblastoma (GBM) to multimodality therapy with cetuximab, temozolomide and radiation

Epidermal growth factor receptor (EGFR) mutation status and Rad51 determine the response of glioblastoma (GBM) to multimodality therapy with cetuximab, temozolomide and radiation

Purpose: EGFR amplification and mutation (i.e., EGFRvIII) are found in 40% of primary GBM tumors and are believed to contribute to tumor development and therapeutic resistance. This study was designed to investigate how EGFR mutational status modulates response to multimodality treatment with cetu...

Full description

Bibliographic Details
Main Authors: Phyllis Rachelle Wachsberger, Richard Yaacov Lawrence, Yi eLiu, Barbara eRice, Constantine eDaskalakis, Adam P Dicker
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-02-01
Series:Frontiers in Oncology
Subjects:
radiation therapy
EGFR
cetuximab
GBM
RAD51
temozolomide
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00013/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00013/full

Similar Items